ClinicalTrials.gg
WithdrawnNCT03181880ASTUTEUpdated Jul 2, 2017

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease

A Phase 4 interventional study of Aclidinium bromide/formoterol fumarate combination and Standard of Care in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Study stopped early as AZ have re-prioritised to focus on research to help bring existing and innovative medicines to more patients with asthma and COPD.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.

Enrollment
27th of 27
0 · median 561
Started
2017
with 1 other
Phase 4
6 of 28
none open now
Registered
28th of 28
by date
Lead sponsor
25 of 28
AstraZeneca

Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 27th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2017, is one of 6 in phase 4, and was the 28th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About aclidinium bromide

aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

ASTUTE is a pragmatic open randomised 12-week multinational trial to evaluate the effectiveness of aclidinium bromide/formoterol fumarate dihydrate fixed-dose combination compared to standard of care bronchodilators in chronic obstructive pulmonary disease.

Read the detailed description

ASTUTE is a longitudinal, randomised, multicentre, and multinational pragmatic study of patients with Chronic Obstructive Pulmonary Disease to evaluate the comparative effectiveness of Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®) and Standard of Care bronchodilators in patients treated with long acting bronchodilator monotherapies OR patients who abide to the following treatment category: patient is newly diagnosed, or naïve to maintenance therapy, or treated with short-acting bronchodilators as rescue medication, or has not been treated with long-acting bronchodilators in the last 3 months.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • ASTUTE
  • Chronic Obstructive Pulmonary Disease
  • Randomised
  • Pragmatic
  • Standard of Care
  • Aclidinium bromide/formoterol fumarate fixed-dose combination
  • Duaklir
  • Genuair
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient is aged 40 years or older;

  • Confirmed diagnosis of ;
  • Spirometry performed at study entry or within the last 3 months preceding study entry with a post-bronchodilator /Forced Vital Capacity quotient less than 0.7;
  • Patient is a current smoker or an ex-smoker with a smoking history of ≥10 pack-years;
  • Patient belongs to any of these treatment groups:

    • Patient is treated by a monotherapy long-acting bronchodilator (Long-Acting Muscarinic Antagonist or Long-Acting Beta Agonist), or
    • Naïve COPD patient, defined as:
  • Patient is newly diagnosed, or
  • Patient is naïve to maintenance therapy, or
  • Patient is treated with short acting bronchodilators as rescue medication, or
  • Patient has not been treated with long acting bronchodilators in the last 3 months.

Exclusion criteria

Exclusion Criteria:

-

Patients should not be included in the study if any of the following exclusion criteria applies:

  • Patient changed treatment regimen over the preceding 3 months;
  • Patient treated or intended to be treated at the time of randomisation with a maintenance regimen of inhaled or inhaled corticosteroids-containing medications;
  • Patient treated or intended to be treated at the time of randomisation with aclidinium bromide/formoterol fumarate dihydrate inhalation powder;
  • Patient had a previous diagnosis of asthma or is suspected of having asthma, asthma-COPD overlap or any other chronic respiratory disease other than COPD (including severe ones, such as cystic fibrosis, pulmonary fibrosis, active neoplasm except adequately treated [no evidence of recurrence within 5 years], active tuberculosis);
  • Patient developed a respiratory tract infection or COPD exacerbation within 6 weeks (or 3 months if an exacerbation-related hospitalisation was required) before the randomisation visit;
  • Patient with a history of reaction to inhaled anticholinergics, sympathomimetic amines, lactose monohydrate, inhaled medication, or any component thereof (including report of paradoxical bronchospasm);
  • Patient has been previously enrolled in the current study.
  • Any condition that in the Investigator's opinion, would limit a patient's ability to participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Aclidinium/formoterol

    Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination

    Drug: Aclidinium bromide/formoterol fumarate combination

  • Active comparator
    Bronchodilators

    The comparator arm consists of SOC.

    Drug: Standard of Care

Interventions

  • DrugAclidinium bromide/formoterol fumarate combination

    Drug pages: Aclidinium bromide · Formoterol

    Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators. The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®). Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment.

    Also known as: Duaklir™ Genuair®

  • DrugStandard of Care

    Brochodilators

06

What researchers measure

Primary outcomes

  1. Change from baseline in overall early morning COPD symptom severity score of aclidinium bromide/formoterol fumarate dihydrate inhalation powder vs. Standard of Care bronchodilators as measured by the Early Morning Symptoms of COPD Instrument over 12 wks.

    Changes from baseline compared between aclidinium bromide/formoterol fumarate dihydrate inhalation powder and Standard of Care bronchodilators. Baseline values for EMSCI will be averaged over the study entry and previous day. For longitudinal analyses, each daily measure will be aggregated on a weekly (7 days) basis during the weeks of measurement (weeks 4, 8, and/or 12) by taking the mean value of all available measurements during the week.

    Time frame: study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84

  2. Change from baseline in overall night time COPD symptom severity score of aclidinium bromide/formoterol fumarate dihydrate inhalation powder vs. Standard of Care bronchodilators as measured by the Nighttime Symptoms of COPD Instrument over 12 weeks.

    Changes from baseline compared between aclidinium bromide/formoterol fumarate dihydrate inhalation powder and Standard of Care bronchodilators. Baseline values for NiSCI will be averaged over the study entry and previous day. For longitudinal analyses, each daily measure will be aggregated on a weekly (7 days) basis during the weeks of measurement (weeks 4, 8, and/or 12) by taking the mean value of all available measurements during the week.

    Time frame: study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84

Secondary outcomes

  1. Change from baseline in daily RS total Score of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the E-RS™COPD scale over 12 weeks.

    Baseline values of the RS-Total Score will be collected and averaged at the study entry visit and previous day. The secondary effectiveness variable will be estimated by the change from baseline in daily RS-Total Score over 12 weeks of treatment.

    Time frame: study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84

  2. Change from baseline in health status of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilatorsmeasured by the COPD assessment Test (CAT) over 12 weeks.

    The CAT measures the health status of patients with COPD. If the response to 1 of the 8 items is missing, the score will be considered missing. Change from baseline in health status over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12) will be calculated. These change scores will be the CAT endpoint.

    Time frame: study entry, days 28, 56 and 84

  3. Change from baseline in total time index of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the Yale Physical Activity Survey (YPAS) over 12 weeks.

    The Total Time Index will be calculated at baseline and over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12). Change from baseline will be calculated. These change scores will be the Total Time Index analysed.

    Time frame: study entry, days 28, 56 and 84

  4. Change from baseline in Energy Expenditure Index of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the Yale Physical Activity Survey (YPAS) over 12 weeks.

    The Energy Expenditure Index will be calculated at baseline and over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12). Change from baseline will be calculated. These change scores will be the Energy Expenditure Index analysed.

    Time frame: study entry, days 28, 56 and 84

  5. Change from baseline in Activity Dimensions Summary Index of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the Yale Physical Activity Survey (YPAS) over 12 weeks.

    The Activity Dimensions Summary Index will be calculated at baseline and over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12). Change from baseline will be calculated. These change scores will be the Activity Dimensions Summary Index analysed.

    Time frame: study entry, days 28, 56 and 84

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2017; primary completion for Dec 2018, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2017
First posted
Jun 9, 2017
StartEst.
Dec 4, 2017
Primary completionEst.
Dec 3, 2018
CompletionEst.
Dec 3, 2018
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03181880
Lead sponsor
AstraZeneca
Collaborators
QuintilesIMS, Inc.
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Dec 4, 2017 (estimated)
Primary completion
Dec 3, 2018 (estimated)
Completion
Dec 3, 2018 (estimated)
Last update
Jul 2, 2017

Study contacts

Anna Ribera
study director · AstraZeneca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aclidinium bromide · Formoterol

Start the discussion